This concept defines the domain of cardiac enzyme therapeutics within clinical pharmacology and biochemistry, specifically addressing the theoretical application of exogenous or endogenous enzymes in myocardial infarction management. It establishes the rule that enzymatic agents facilitate the degradation of specific pathophysiological substrates, such as fibrin clots or toxic lipid metabolites, to restore hemodynamic function. The theory operates under the formal framework of catalytic intervention, where the enzyme's specificity and turnover rate determine therapeutic efficacy while adhering to constraints of biological compatibility and clearance kinetics.
Prerequisite chain context: requires Enzyme Inhibition and Regulation Mechanisms.